

Special Issue

Advances in Targeted At-211 Alpha Therapy

Message from the Guest Editors

Astatine-211 (^{211}At), an alpha-emitting radionuclide, has emerged as a promising isotope for targeted radiotherapy, offering potent and localized cytotoxicity against disseminated cancers. This Special Issue will showcase advances spanning the entire field of ^{211}At research—from targetry, chemistry (separation and radiolabeling), and automation to innovative labeling strategies. In addition, the development and evaluation of astatinated biomolecules (small molecule, peptide, or antibody), and studies elucidating biological mechanisms of action, dosimetry, and other research. In this Special Issue of *Biomolecules*, we invite original research articles, comprehensive reviews, and perspective papers focusing on innovations in ^{211}At chemistry, biology, and radiopharmaceutical applications. By gathering recent insights and technological breakthroughs, this collection aims to accelerate progress toward the safe, reliable, and widespread use of ^{211}At in targeted alpha therapy.

Guest Editors

Dr. Hsiaoju Sharon Lee

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Dr. Yawen Li

Radiochemistry Division, Department of Radiation Oncology, University of Washington, Seattle, WA 98105, USA

Deadline for manuscript submissions

30 September 2026



Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/258249

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)





Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)